Objectives. A high proportion of children with JIA will develop intolerance to MTX with anticipatory and associative gastrointestinal adverse effects. Parents and physicians frequently try to alleviate these symptoms with a variety of countermeasures. The objective of this study was to investigate the course of MTX intolerance within a 6 month period, and the effects of countermeasures on MTX intolerance severity.
Introduction
MTX is effective in the treatment of children with inflammatory joint diseases, with a substantial body of evidence to support its use [1, 2] . Unlike high-dose MTX therapy in cancer patients, treatment with low-dose MTX in JIA exhibits few, and usually transient, adverse effects such as hepatotoxicity and bone marrow suppression [1] .
A recent study has demonstrated that approximately half of JIA patients treated with MTX develop intolerance with anticipatory and associative gastrointestinal adverse effects [3] . MTX intolerance seems to develop within the first year of treatment [4] . After this time period, it is unclear if MTX intolerance improves or worsens over time. Parents and rheumatological care providers frequently try to alleviate these symptoms with a variety of countermeasures against nausea. Despite occasional successes enabling continued use of the medication, the efficacy of these measures has not been tested.
The objectives of this study were (i) to describe the course of MTX intolerance in paediatric patients over a period of 6 months and (ii) to investigate the effect of common countermeasures on the severity of MTX intolerance.
Methods

Patients
Consecutive patients admitted to the German Centre for Paediatric and Adolescent Rheumatology from October 2012 until December 2014 were included in this study. Inclusion criteria were diagnosis of JIA according to ILAR criteria and treatment with MTX for at least 3 months prior to inclusion. Exclusion criteria were other diseases leading to nausea and/or abdominal complaints, and concomitant medications possibly inducing nausea (excepting biologics and NSAIDs). Written consent was obtained from the parents prior to inclusion in the study. The study was approved by the ethics committee of the Bavarian College of Physicians, Munich, Germany.
Data extraction
The following data were extracted from patient files: age, gender, body weight and height, age at diagnosis, duration of disease, MTX dose, route of administration and folic acid supplementation. In addition, treatment with NSAIDs and TNFa antagonists was documented. Intolerance to MTX was determined using the Methotrexate Intolerance Severity Score (MISS) questionnaire, previously developed and validated in JIA [3] . The MISS consists of four domains, namely abdominal pain, nausea, vomiting and behavioural symptoms, assessing symptoms after MTX administration, and anticipatory and associative symptoms. The behavioural symptoms domain includes restlessness, irritability and refusal of MTX, which develop in response to MTX-induced gastrointestinal symptoms and anticipation thereof. A patient could score 0 (no symptoms), 1 (mild symptoms), 2 (moderate symptoms) or 3 (severe symptoms) points on each item. MTX intolerance was defined as 56 points, including at least one anticipatory, associative or behavioural symptom [3] .
Countermeasures were classified into four groups: antiemetic drugs, covert dosing, taste masking and alternative/complementary medicine. MTX dose, MISS score and countermeasures instituted by the parents were determined at inclusion, and for patients with MTX intolerance at three additional points in time ($2 months apart) by questionnaire.
Statistical analysis
Associations of demographic or treatment factors with MISS scores between MTX tolerant and intolerant patients were analysed using univariate parametric or non-parametric statistics (chi-square testing or MannWhitney U test, Student's t test or analysis of variance), where appropriate. MISS score changes over time were analysed using repeated-measures analysis of variance after logarithmic transformation.
MTX intolerant patients were grouped into two categories: any use of countermeasures, and no countermeasures used at time of inclusion. Linear regression analyses between use of countermeasures and MISS score at time of inclusion were performed using single measure analysis of variance. Where data on all time points were available, analysis between use of countermeasures and MISS score over time was performed using mixed betweenwithin subject analysis of variance. As no countermeasure had been previously shown to exhibit a stronger effect on MTX intolerance prior to initiating the study, it was assumed that all countermeasures would have a similar effect on MTX intolerance. Therefore MISS scores from patients with the different countermeasures were pooled for the purposes of analysis.
The effects of specific countermeasures were also analysed: when countermeasures were instituted, the effect was measured at the next time point; all instances where a specific countermeasure was instituted were analysed collectively using the Wilcoxon rank-sum test.
Sensitivity analysis
To account for possible bias in the application of parental countermeasures, for each patient the probability that this patient belonged to the intervention group (any use of countermeasure) was calculated using all documented variables at time of inclusion in a saturated logistic regression model (propensity score). Cases with propensity score >0.9 were excluded to avoid extrapolation. The Pearson product-moment correlation coefficient was computed to assess the relationship between the propensity score and MISS scores at time of inclusion. Linear regression analysis between use of countermeasures and MISS score were performed using propensity score as a covariate using singlemeasure and mixed betweenwithin subject analysis of variance.
Results
In our study 202 patients met inclusion criteria. Six patients were excluded (refused to participate), leaving 196 patients for analysis. Demographic data of the patients with and without MTX intolerance are shown in Table 1 .
MTX intolerance and change of MISS score over time Ninety patients (46%) showed MTX intolerance (MISS score 56 and at least one anticipatory, associative or behavioural symptom). Patients with MTX intolerance had significantly longer disease duration, as expected from a previous study [3, 4] . Non-significant trends showed longer duration of MTX use, less supplementation of folic acid and a lower dose of MTX to be associated with MTX intolerance. For all other variables, the two groups showed no significant differences except median MISS score, as per design (Table 1 ). Median MISS score of patients with MTX intolerance at inclusion was 11.0 (interquartile range = 8.014.25, mean: 11.84), and did not change significantly at 2, 4 and 6 months (means: 10.00, 11.13, 10.61, P = 0.374).
Use of countermeasures for MTX intolerance
Fifty-seven patients with MTX intolerance (63%) and 19 patients with no MTX intolerance (18%) were using any countermeasures at time of inclusion (diff = 45%, P < 0.001). Patients with MTX intolerance receiving and patients not receiving countermeasures at time of inclusion did not show a significant difference in median MISS scores at inclusion (diff = 1.0, P = 0.344), nor did they show significant differences in MISS scores with repeated measures over time (MISS score (median, range) at 2 months: 7 (024) vs 9 (121); 4 months: 10 (024) vs 9 (029); 6 months: 10 (023) vs 7 (029); b = À0.369, S.E. = 2.12, P = 0.863).
In the sensitivity analysis, the calculated propensity score was not correlated to MISS at inclusion (r = 0.061, P = 0.576), indicating little or no association of MISS severity on the decision to use any countermeasures. Using the propensity score as a covariate in the analysis of MISS scores between patients receiving and not receiving countermeasures did not significantly change the result of the analysis at time of inclusion [F (2, 84) = 0.349, P = 0.706], or with repeated measures (b = À0.811, S.E. = 2.17, P = 0.710).
Newly introduced countermeasures within the study period were measured separately. In 32 of 144 time intervals (22%) between study visits, constituting 374 months of follow-up time, countermeasures were introduced by the parents, with no significant changes in MISS scores after introduction for any modality (Table 2) .
Eight patients stopped MTX during the study period, and nine reduced the dosage, with no significant difference between patients on countermeasures and patients not using countermeasures. 
Discussion
MTX intolerance causes a significant problem in the treatment of children with rheumatic diseases, as MTX is the medication most frequently used, with few side effects caused by toxicity [1, 5] . Anticipatory nausea and vomiting associated with MTX therapy causes severe distress to the child and disruption of family life [6] . It is not surprising that parents use a variety of remedies to alleviate that distress.
In this study we demonstrate that patients with MTX intolerance do not appear to profit from common countermeasures instituted by parents or care providers. Patient intolerance to MTX as measured by MISS scores with and without countermeasures did not differ significantly at any point in time in our study. In addition, institution of new countermeasures during the observation period did not show a significant effect, but in several cases resulted in an even higher MISS score after institution ( Supplementary Fig. S1 , available at Rheumatology Online). It is possible that frustration due to insufficient efficacy has led to worsening of intolerance symptoms in these cases. In this study a little less than half of the patients showed symptoms of anticipatory nausea (MTX intolerance) associated with MTX treatment, similar to other studies of JIA patients [3] . Studies in adults with rheumatic diseases show a prevalence of MTX intolerance of $10%, while anticipatory nausea with MTX in cancer chemotherapy in children and adults is reported at around 20% [7, 8] . The reasons for the observed differences in frequency are unclear; it is possible that the MISS questionnaire overstates MTX intolerance, but other questionnaire-based studies have shown even higher frequencies in adolescents with JIA [9] . Acquisition of MTX intolerance might also be a cumulative process, with higher frequencies in children with rheumatic diseases compared with cancer treatment perhaps reflecting the usually longer duration of treatment in the former. Recommendations for treating MTX intolerance at this time consist of folic acid, changing dose or route of administration or giving antiemetics on administering MTX [10, 11] . At this time, mostly anecdotal evidence supports these recommendations. It has been hypothesized that ondansetron might be better in preventing MTX intolerance if introduced early [12, 13] . Some data exist on the route of administration, where initial studies with the MISS questionnaire showed higher scores in patients on subcutaneous compared with oral MTX therapy [3, 7] . A study with a different questionnaire also demonstrated that subcutaneous dosing was associated with more nausea in a multivariate analysis [9] . A recent study in 55 paediatric patients on MTX found no significant difference in MISS scores at 12 months [14] . The only study investigating the route at initiation of MTX as well as over time found a higher prevalence of behavioural symptoms of MTX intolerance with exclusively subcutaneous dosing, with similar rates of abdominal pain, nausea and vomiting [15] . In this study, route of administration was not shown to be associated with MTX intolerance. To truly investigate the impact of route of MTX administration on intolerance, further research should control for the various confounding factors such as needle phobia, as well as switching routes over time.
MTX intolerance in the form of anticipatory or associated nausea and vomiting can be viewed as a conditioned response [16] . The goal of any countermeasure would be extinction, that is, a decrease of the conditioned response to the conditioned stimulus alone. Of the four examined modalities in this study, antiemetics try to remove the unconditioned stimulus, while taste masking and covert dosing aim to remove the conditioned stimulus. Results of this study suggest that these strategies are not successful in overcoming the conditioned response, which indicates possible additional underlying mechanisms [17] . It is important for parents and physicians to be aware of the limited use of these commonly used strategies, so as not to overvalue them. So far, various behavioural therapies for overcoming classical conditioning have been efficacious [8, 18] . These have been used with some success in chemotherapy-induced anticipatory nausea in children, although prevention remains the mainstay of recommendations here [19] . A small study in nine children with JIA and MTX-related nausea demonstrated some effect of behavioural therapy in approximately half of the patients [20] .
A limitation of this study was the heterogeneity of the intervention, as several countermeasures were employed. It is possible that countermeasures were more or less successful individually. However, prior to this study clinical experience had not shown any individually successful long-term measure for MTX intolerance so that it was considered justifiable to consider the measures in the aggregate and analyse single countermeasures as available (Table 2) . A further limitation of this study was the patient selection, with patients recruited at various stages within their disease as well as MTX treatment periods of varying length. In addition, the decision to implement countermeasures was not determined by randomization, but by indication. We addressed this possible confounding by indication, where patients with more severe symptoms would be more likely to receive countermeasures by calculating a propensity score for use of countermeasures on the basis of available data. Sensitivity analysis using this propensity score demonstrated no difference, showing either no bias or insufficient data to control for this. Furthermore, the study follow-up period of 6 months only allowed for an observation of general trends. However, the strength of this study is the prospective collection of the largest dataset of children with JIA on MTX so far, evaluating common countermeasures for MTX intolerance used in daily practice. Further research is indicated in this area, including randomized, controlled trials of the specific countermeasures with adequate follow-up time.
In conclusion, patients with JIA showing MTX intolerance cannot expect a decrease of intolerance symptoms, at least in the short term. Various modalities used by the parents of JIA patients or their care providers as countermeasures against MTX intolerance symptoms showed no discernible effect. Further studies should consider behavioural therapy or other measures aiming at the conditioned MTX response.
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